Akebia Therapeutics (AKBA) holder files to sell 341,305 shares in Rule 144 trade

Rhea-AI Filing Summary

Akebia Therapeutics insider-related holders filed a notice to sell up to 341,305 shares of common stock under Rule 144. The proposed sale has an aggregate market value of $475,950.00 and is expected to be executed through Morgan Stanley Smith Barney LLC on Nasdaq around 02/02/2026.

The filing notes that these shares are common stock and indicates that 265,365,993 shares of this class were outstanding, providing scale for the planned sale. The shares to be sold were acquired as restricted stock from Akebia Therapeutics, Inc. on 01/31/2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	341305	475950.00	265365993	02/02/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock	Akebia Therapeutics, Inc.			341305	02/02/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Akebia Therapeutics (AKBA) Rule 144 filing disclose?

The filing discloses a planned sale of 341,305 Akebia Therapeutics common shares under Rule 144. These shares, with an aggregate market value of $475,950.00, are proposed to be sold through Morgan Stanley Smith Barney LLC on Nasdaq around February 2, 2026.

How many Akebia Therapeutics (AKBA) shares are planned for sale under this notice?

The notice covers a proposed sale of 341,305 shares of Akebia Therapeutics common stock. The filing also states that 265,365,993 shares of this class were outstanding, helping investors understand the relative size of the potential transaction compared with total shares.

What is the aggregate market value of the Akebia (AKBA) shares in the Rule 144 sale?

The aggregate market value of the shares covered by this Rule 144 notice is $475,950.00. This figure reflects the total value of the 341,305 common shares proposed for sale, based on the price reference used when preparing the disclosure document.

When were the Akebia Therapeutics (AKBA) shares to be sold acquired?

The shares to be sold were acquired on January 31, 2026, as restricted stock from Akebia Therapeutics, Inc. itself. This acquisition date and nature of the transaction are disclosed in the section detailing how and when the securities were originally obtained.

On which exchange are the Akebia (AKBA) Rule 144 shares expected to be sold?

The filing indicates that the common stock covered by this Rule 144 notice is expected to be sold on Nasdaq. Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, New York, is listed as the broker handling the proposed transaction.

What type of Akebia Therapeutics (AKBA) security is involved in this Form 144?

The security involved is Akebia Therapeutics common stock. The notice specifies that 341,305 common shares are to be sold, identifies them as restricted stock originally, and provides context with the total outstanding common shares figure stated in the document.